Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Yangzi Li, Sining Liu, Qingya Cui, Lingling Liu, Zheng Li, Wei Cui, Mengyun Li, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6803.

https://doi.org/10.1182/blood-2023-184505

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Aliya Rashid, William Wesson, Forat Lutfi, Muhammad Umair Mushtaq, Joseph P McGuirk, Al-Ola Abdallah, Wei Cui, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2023-182126

Published: 2023

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Polina Bellman, Wei Cui, Zahra Mahmoudjafari, Shebli Atrash, Barry Paul, Hamza Hashmi, Rajesh Banderudrappagari, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 8074–8075.

https://doi.org/10.1182/blood-2022-168450

Published: 2022

Journal Articles

Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients

Evguenia Ouchveridze, Chandandeep Singh, Shebli Atrash, Barry Paul, Meera Mohan, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah, Hamza Hashmi

Blood (2022) 140 (Supplement 1): 7164–7165.

https://doi.org/10.1182/blood-2022-168368

Published: 2022

Journal Articles

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone

Jayanshu Jain, Ghena Khasawneh, Hamza Hashmi, Meera Mohan, Zahra Mahmoudjafari, Wei Cui, Joseph P. McGuirk, Leyla O. Shune, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash

Blood (2022) 140 (Supplement 1): 10587–10588.

https://doi.org/10.1182/blood-2022-165828

Published: 2022

Journal Articles

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

William Wesson, Wei Cui, Muhammad Mushtaq, Rajat Bansal, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Ramesh Balusu, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 12781–12783.

https://doi.org/10.1182/blood-2022-160437

Published: 2022

Journal Articles

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haiping Dai, Wei Cui, Hongjie Shen, Qian Wang, Jia Yin, Zheng Li, Depei Wu, Xiaowen Tang

Blood (2022) 140 (Supplement 1): 10345–10346.

https://doi.org/10.1182/blood-2022-166687

Published: 2022

Journal Articles

Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

Aytaj Mammadzadeh, Fulei Peng, Shebli Atrash, Hamza Hashmi, Meera Mohan, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah

Blood (2022) 140 (Supplement 1): 4277–4278.

https://doi.org/10.1182/blood-2022-165762

Published: 2022

Journal Articles

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Peng Li, Sara Brown, Margaret Williams, Thomas White, Wei Xie, Wei Cui, Deniz Peker, Li Lei, Christian A. Kunder, Huan-You Wang, Sarah S. Murray, Jennie Vagher, Tibor Kovacsovics, Jay L. Patel

Blood (2022) 140 (7): 716–755.

https://doi.org/10.1182/blood.2021015135

Published: 2022

Includes: Supplemental data

Journal Articles

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Haiping Dai, Yang Lin, Huimin Meng, Qingya Cui, Wenjuan Zhu, Xiaowen Tang, Wei Cui, Depei Wu

Blood (2021) 138 (Supplement 1): 4817.

https://doi.org/10.1182/blood-2021-151587

Published: 2021

Journal Articles

Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma

Tahani Atieh, Shebli Atrash, Meera Mohan, Leyla Shune, Zahra Mahmoudjafari, Julie Quick, Justin Riffel, Joseph P. McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah, Nausheen Ahmed, Wei Cui, Anne Wishna

Blood (2021) 138 (Supplement 1): 1642.

https://doi.org/10.1182/blood-2021-149791

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Lei Yu, Liqing Kang, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2021-152565

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Yunju Ma, Changju Qu, Haiping Dai, Sining Liu, Qingya Cui, Wei Cui, Jia Yin, Liqing Kang, Xiaying Lian, Huiying Qiu, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2021-152041

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Baoquan Song, Depei Wu, MDPhD, Xiaowen Tang, MD PhD, Jia Yin, Zheng Li

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-143474

Published: 2020

Journal Articles

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaowen Tang, MD PhD, Depei Wu, MDPhD, Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Baoquan Song, Wei Cui, Jia Yin, Zheng Li, Lei Yu, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141602

Published: 2020

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

Journal Articles

Decitabine Combined with Haag Regimen Is an Effective Salvage Treatment for Advanced Acute Myeloid Leukemia

XiaoWen Tang, MD, Wei Cui, Zhengming Jin, Xiaming Zhu, Aining Sun, PhD, Huiying Qiu, Miao Miao, Jing Cao, Dandan Guo, Depei Wu, MD PhD

Blood (2016) 128 (22): 5205.

https://doi.org/10.1182/blood.V128.22.5205.5205

Published: 2016

NARROW

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

BCMA Re-Emergence As a Prognostic Indicator of Clinical Relapse after Chimeric Antigen Receptor T-Cell Therapy (CART) in Multiple Myeloma

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Decitabine Combined with Haag Regimen Is an Effective Salvage Treatment for Advanced Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only